Biopharma quality control is being revolutionized by advanced analytics and digital transformation through a synergy that ...
As drug-resistant infections threaten to undermine decades of medical progress, scientists are increasingly turning to ...
For decades in life sciences, pharmacovigilance (PV)—a critical reinforcer of drug safety—has been a reactive function. Its remit has been to collect details of adverse events (side-effects of ...
As AI reshapes biotechnology, stakeholders are acting to establish governance to maintain safety and efficacy standards.
Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via a new AI platform. The machine learning platform, called Lilly TuneLab, allows selected ...
Machine vision systems perform high-speed inspections with sub-millimeter precision, capturing images of every product for real-time AI analysis without fatigue or subjective judgment. Physical AI and ...
Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets ...
Hosted on MSN
Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development
Eli Lilly and Nvidia are partnering to build what the companies call the pharmaceutical industry's "most powerful" supercomputer and so-called AI factory to help accelerate drug discovery and ...
Sept 2 (Reuters) - Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in ...
A corridor at Insilico Medicine’s Robotics Lab in Suzhou, China. Insilico will partner with Eli Lilly on an artificial intelligence (AI) based drug development collaboration that they said could ...
Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...
In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results